ft 22 apr 94 uk compani news sb rise pound 353m despit declin european sale strong growth us drug sale volum fail offset declin europ first quarter 1994 smithklin beecham healthcar group total drug sale fell 1 per cent pound 874m pound 886m although currenc effect strip sale 1 per cent better perform divis anim health consum healthcar clinic laboratori push group pre tax profit 15 per cent pound 353m pound 307m result earn 8 7p per share 7 5p dividend quarter rais 18 per cent 3p reflect manag confid futur compani share rose 8p 372p reflect drug sector recent acquir respons yield consider group turnov pound 1 48bn pound 1 52bn figur depress sale person care busi contribut pound 53m first quarter 1993 pharmaceut divis clearli split sharp rise sale newer product declin establish drug sale ulcer treatment tagamet whose us patent expir next month 3 per cent lower constant currenc term pound 153m sale antibiot augmentin compani biggest product fell 8 per cent pound 191m hit measur implement januari cut itali drug bill also affect sb product measur sinc revers best perform newer drug anti depress seroxat paxil sale sharpli pound 77m new launch kytril anti emet chemotherapi patient doubl sale pound 29m compet directli one star glaxo portfolio zofran group counter medicin busi receiv boost second quarter launch otc version tagamet increas sale 11 per cent pound 150m see lex